Detalhe da pesquisa
1.
CYP2C8-Mediated Formation of a Human Disproportionate Metabolite of the Selective NaV1.7 Inhibitor DS-1971a, a Mixed Cytochrome P450 and Aldehyde Oxidase Substrate.
Drug Metab Dispos
; 50(3): 235-242, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34930785
2.
Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours.
Br J Clin Pharmacol
; 84(1): 112-121, 2018 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-28865153
3.
Coadministration of probenecid and cimetidine with mirogabalin in healthy subjects: A phase 1, randomized, open-label, drug-drug interaction study.
Br J Clin Pharmacol
; 84(10): 2317-2324, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29920736
4.
Effect of coadministration of metformin with mirogabalin: Results from a phase 1, randomized, open-label, drug-drug interaction studyâ©.
Int J Clin Pharmacol Ther
; 56(10): 451-458, 2018 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-30049303
5.
Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate.
Circulation
; 131(1): 82-90, 2015 Jan 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-25403645
6.
Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine.
Br J Clin Pharmacol
; 82(6): 1591-1600, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27530188
7.
Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal.
Crit Care
; 20(1): 273, 2016 Sep 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-27659071
8.
Metabolism and disposition of [(14)C]tivantinib after oral administration to humans, dogs and rats.
Xenobiotica
; 44(11): 996-1008, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24911380
9.
Pharmacokinetics, Pharmacodynamics, and Safety of Edoxaban in Pediatric Subjects: A Phase I Single-Dose Study.
Clin Pharmacol Ther
; 2024 Feb 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38369608
10.
Relative Bioavailability of Omaveloxolone When Capsules Are Sprinkled Over and Mixed in Applesauce Compared With Administration as Intact Omaveloxolone Capsules: A Phase 1, Randomized, Open-Label, Single-Dose, Crossover Study in Healthy Adults.
J Clin Pharmacol
; 2024 Jun 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38837775
11.
A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors.
Invest New Drugs
; 31(4): 1016-22, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23417696
12.
Pharmacokinetics of the Multi-kinase Inhibitor Pexidartinib: Mass Balance and Dose Proportionality.
Clin Pharmacol Drug Dev
; 12(2): 159-167, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36369799
13.
Dosing Recommendation Based on the Effects of Different Meal Types on Pexidartinib Pharmacokinetics in Healthy Subjects: Implementation of Model-informed Drug Development Strategy.
Clin Pharmacol Drug Dev
; 12(5): 475-483, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36942508
14.
A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies.
Cancer
; 118(21): 5403-13, 2012 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22570147
15.
Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects.
Clin Pharmacokinet
; 61(11): 1623-1639, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36264536
16.
Phase I studies of the safety, tolerability, pharmacokinetics, and pharmacodynamics of DS-1211, a tissue-nonspecific alkaline phosphatase inhibitor.
Clin Transl Sci
; 15(4): 967-980, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35021269
17.
Effect of Mild and Moderate Hepatic Impairment (Defined by Child-Pugh Classification and National Cancer Institute Organ Dysfunction Working Group Criteria) on Pexidartinib Pharmacokinetics.
J Clin Pharmacol
; 62(8): 992-1005, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35247274
18.
Evaluation of Potential Drug-Drug Interaction Risk of Pexidartinib With Substrates of Cytochrome P450 and P-Glycoprotein.
J Clin Pharmacol
; 61(3): 298-306, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32918831
19.
Exposure-response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor.
CPT Pharmacometrics Syst Pharmacol
; 10(11): 1422-1432, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34585528
20.
Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors.
J Clin Pharmacol
; 61(4): 480-492, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33043474